Gross G, Huber G. Schizophrenia: neurodevelopmental disorder or degenerative brain process? Fortschr Neurol Psychiatr. 2008;76(1):S57–62.

Article  PubMed  Google Scholar 

Tripathi A, Kar SK, Shukla R. Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies. Clin Psychopharmacol Neurosci. 2018;16(1):7–17.

Article  PubMed  PubMed Central  Google Scholar 

Avila J, Villacrés L, Rosado D, Loor E. Cognitive deterioration and quality of life in patients with schizophrenia: a single institution experience. Cureus. 2020;12(1):e6772–7.

PubMed  PubMed Central  Google Scholar 

Lungu PF, Lungu CM, Ciobica A, Balmus IM, Vitalaru R, Mavroudis I, Dobrin R, Cimpeanu M, Gurzu IL. The effect of antipsychotics on cognition in schizophrenia—a current narrative review. Brain Sci. 2024;14(4):359.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toulopoulou T, Goldberg TE, Mesa IR, Picchioni M, Rijsdijk F, Stahl D, et al. Impaired intellect and memory: a missing link between genetic risk and schizophrenia? Arch Gen Psychiatry. 2010;67:905–13.

Article  PubMed  Google Scholar 

Gascon E, Vutskits L, Kiss JZ. Polysialic acid-neural cell adhesion molecule in brain plasticity: from synapses to integration of new neurons. Brain Res Rev. 2007;56(1):101–18.

Article  CAS  PubMed  Google Scholar 

Piras F, Schiff M, Chiapponi C, Bossù P, Mühlenhoff M, Caltagirone C, et al. Brain structure, cognition and negative symptoms in schizophrenia are associated with serum levels of polysialic acid-modified NCAM. Transl Psychiatry. 2015;5(10):e658–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keshri N, Nandeesha H, Rajappa M, Menon V. Relationship between neural cell adhesion molecule-1 and cognitive functioning in schizophrenia spectrum disorder. Indian J Clin Biochem. 2022;37(4):494–8.

Article  CAS  PubMed  Google Scholar 

Chu CS, Li DJ, Chu CL, Wu CC, Lu T. Decreased IL-1ra and NCAM-1/CD56 serum levels in unmedicated patients with schizophrenia before and after antipsychotic treatment. Psychiatry Investig. 2018;15(7):727–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

An H, Zhou L, Yu Y, Fan H, Fan F, Tan S, et al. Serum NCAM levels and cognitive deficits in first episode schizophrenia patients versus health controls. Schizophr Res. 2018;192:457–8.

Article  PubMed  Google Scholar 

Zhang W, Xiao MS, Ji S, Tang J, Xu L, Li X, et al. Promoter variant rs2301228 on the neural cell adhesion molecule 1 gene confers risk of schizophrenia in Han Chinese. Schizophr Res. 2014;160(1):88–96.

Article  PubMed  Google Scholar 

Chen X, Tang J, Liu Y, Luan M, An K, Zhang Y, et al. Lack of association between NCAM1 and early onset schizophrenia in a family based study in Shandong peninsula of China. J Pediatr Genet. 2012;01(01):39–45.

Article  CAS  Google Scholar 

Shaw AD, Tiwari Y, Kaplan W, Heath A, Mitchell PB, Schofield PR, et al. Characterisation of genetic variation in ST8SIA2 and its interaction region in NCAM1 in patients with bipolar disorder. PLoS ONE. 2014;9(3):e92556–64.

Article  PubMed  PubMed Central  Google Scholar 

Atz ME, Rollins B, Vawter MP. NCAM1 association study of bipolar disorder and schizophrenia: polymorphisms and alternatively spliced isoforms lead to similarities and differences. Psychiatr Genet. 2007;17(2):55–67.

Article  PubMed  PubMed Central  Google Scholar 

Arai M, Itokawa M, Yamada K, Toyota T, Arai M, Haga S, et al. Association of neural cell adhesion molecule 1 gene polymorphisms with bipolar affective disorder in Japanese individuals. Biol Psychiatry. 2004;55(8):804–10.

Article  CAS  PubMed  Google Scholar 

Xu Z, He Z, Huang K, Tang W, Li Z, Tang R, et al. No genetic association between NCAM1 gene polymorphisms and schizophrenia in the Chinese population. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1633–6.

Article  CAS  PubMed  Google Scholar 

Sullivan PF, Keefe RSE, Lange LA, Lange EM, Stroup TS, Lieberman J, et al. NCAM1 and neurocognition in Schizophrenia. Biol Psychiatry. 2007;61(7):902–10.

Article  CAS  PubMed  Google Scholar 

Rabinowitz J, Rabinowitz AA. Outlier-response pattern checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS). Psychiatry Res. 2021;303:114114.

Article  PubMed  Google Scholar 

Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke’s Cognitive Examination III in frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord. 2013;36(3–4):242–50.

Article  PubMed  Google Scholar 

Charernboon T, Chompookard P. Detecting cognitive impairment in patients with schizophrenia with the Addenbrooke’s Cognitive Examination. Asian J Psychiatr. 2019;40:19–22.

Article  PubMed  Google Scholar 

Peixoto B, Machado M, Rocha P, Macedo C, Machado A, Baeta É, et al. Validation of the Portuguese version of Addenbrooke’s Cognitive Examination III in mild cognitive impairment and dementia. Adv Clin Exp Med. 2018;27(6):781–6.

Article  PubMed  Google Scholar 

Jesudas BR, Nandeesha H, Menon V, Allimuthu P. Relationship of elevated neural cell adhesion molecule 1 with interleukin-10 and disease severity in bipolar disorder. Asian J Psychiatry. 2020;47:101849–56.

Article  Google Scholar 

Tanaka Y, Yoshida S, Shimada Y, Ueda H, Asai K. Alteration in serum neural cell adhesion molecule in patients of schizophrenia. Hum Psychopharmacol. 2007;22(2):97–102.

Article  CAS  PubMed  Google Scholar 

Hidese S, Hattori K, Sasayama D, Miyakawa T, Matsumura R, Yokota Y, et al. Cerebrospinal fluid neural cell adhesion molecule levels and their correlation with clinical variables in patients with schizophrenia, bipolar disorder, and major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2017;76:12–8.

Article  CAS  PubMed  Google Scholar 

Bisaz R, Schachner M, Sandi C. Causal evidence for the involvement of the neural cell adhesion molecule, NCAM, in chronic stress-induced cognitive impairments. Hippocampus. 2011;21(1):56–71.

Article  PubMed  Google Scholar